



## ASGO Webinar Series #37

Title

What is the best surgical management for early cervical cancer less than 2 cm?

# Discussion

**Kittipat Charoenkwan**

Chiang Mai University, Thailand

# Declaration of interest

No conflict of interest with regard to this topic

## Prospective data addressing the outcomes of simple hysterectomy (SH) plus pelvic node dissection for low-risk, early-stage cervical cancer

Studies	Design/Sample size	Inclusion criteria	Main outcomes
<b>ConCerv</b> 2010-2019 USA	Prospective, single-arm, multicenter study (14 sites, 9 countries)/ <b>40 patients: conization                      followed by SH</b> <b>16 patients: inadvertent SH</b> <span style="background-color: red; color: white; padding: 2px;"><b>96% MIS</b></span>	FIGO stage IA2-IB1 Squamous (any grade)/Adeno (G1/2) Tumor size $\leq$ 2 cm Depth of invasion $\leq$ 10 mm No LVSI Negative imaging for metastasis Negative conization margin	<b>2-year recurrent rate</b> <ul style="list-style-type: none"> <li>• Conization + SH: 0% (0/40)</li> <li>• Inadvertent SH: 12.5% (2/16)</li> </ul> <b>Pelvic LN metastasis</b> 5% <span style="background-color: purple; color: white; padding: 2px;"><b>Pelvic LN assessment recommended</b></span>
<b>LESSER</b> 2015-2018 Brazil	Randomized phase II non- inferiority trial (3 centers, Northeast Brazil)/ <b>20 patients: SH</b> <b>20 patients: MRH (type B2)</b> <span style="background-color: red; color: white; padding: 2px;"><b>92.5% Open</b></span>	FIGO stage IA2-IB1 Squamous/Adeno/Adenosquamous Tumor size $\leq$ 2 cm No evidence of advanced disease <span style="background-color: #e91e63; color: white; padding: 2px;"><b>20% had tumor &gt; 2 cm on final pathology</b></span>	<b>3-year disease-free survival</b> SH: 95% MRH: 100% (p=0.30) SH: shorter operative time and urinary catheter removal time

# Low-risk, early-stage cervical cancer (SHAPE trial)

FIGO stage IA2-IB1

Squamous/Adeno/Adenosquamous

Tumor size  $\leq 2$  cm

Stromal invasion

❖  $< 10$  mm on LEEP/cone

❖  $< 50\%$  on MRI


## Question 1

What are acceptable methods for assessment of tumor size and extent of stromal invasion in low-resource settings? Is the clinical estimation of tumor size acceptable? Should conization be done to assess the depth of invasion prior to offering a simple hysterectomy if MRI is not done?

## Question 2

If simple hysterectomy (instead of RH) and pelvic LN assessment are performed in low-risk early-stage cervical cancer through the use of a minimally invasive approach, **what is your opinion regarding the techniques to prevent tumor spillage during colpotomy?**

- Is the creation of a vaginal cuff still needed during a simple hysterectomy?



Images from: Kanao H, et al. *J Gynecol Oncol* 2019;30:e71

## Question 3

Would the results of the SHAPE trial be applicable to **women who undergo an inadvertent simple hysterectomy** with a postoperative diagnosis of cervical cancer?